B

BioLine RX Ltd
TASE:BLRX

Watchlist Manager
BioLine RX Ltd
TASE:BLRX
Watchlist
Price: 1.5 ILS -6.25%
Market Cap: 34.4m ILS

BioLine RX Ltd
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

BioLine RX Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
B
BioLine RX Ltd
TASE:BLRX
Revenue
$12.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Kamada Ltd
NASDAQ:KMDA
Revenue
$174.8m
CAGR 3-Years
15%
CAGR 5-Years
5%
CAGR 10-Years
10%
Urogen Pharma Ltd
NASDAQ:URGN
Revenue
$96.5m
CAGR 3-Years
16%
CAGR 5-Years
91%
CAGR 10-Years
N/A
Entera Bio Ltd
NASDAQ:ENTX
Revenue
$124k
CAGR 3-Years
-25%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
Pluri Inc
NASDAQ:PLUR
Revenue
$1.3m
CAGR 3-Years
60%
CAGR 5-Years
125%
CAGR 10-Years
13%
M
Matricelf Ltd
TASE:MTLF
Revenue
₪0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

BioLine RX Ltd
Glance View

Market Cap
34.4m ILS
Industry
Biotechnology

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which focuses on oncology. The firm is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The firm is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

BLRX Intrinsic Value
4.01 ILS
Undervaluation 63%
Intrinsic Value
Price
B

See Also

What is BioLine RX Ltd's Revenue?
Revenue
12.7m USD

Based on the financial report for Sep 30, 2025, BioLine RX Ltd's Revenue amounts to 12.7m USD.

What is BioLine RX Ltd's Revenue growth rate?
Revenue CAGR 1Y
-42%

Over the last year, the Revenue growth was -42%.

Back to Top